Clinical Benefits and Cost Effectiveness of Vagus Nerve Stimulation in a Long-term Treatment of Patients with Major Depression

 

 Buy Article Permissions and Reprints

Abstract

Background: To evaluate clinical aspects and cost effectiveness of the treatment with vagus nerve stimulation (VNS), a group of 9 VNS-implanted patients and 9 age- and sex-matched patients suffering from treatment-resistant depression were included in a prospective study.

Methods: The psychopathological ratings over 12 months as well as socio-economic data on the duration of hospitalisation, frequency of outpatient treatment, and subsequent drug treatment were compared with the pre-implantation period.

Results: Compared with baseline values in the HAMD scale (mean 23.7; SD 2.4), there was a significant (t=14.5; df=8; p<0.001) improvement in symptoms after 12 months’ stimulation (mean 10.2; SD 2.4). The duration of hospitalisation dropped on average by 20 days in the first post-implantation year, the treatment frequency from 33 to 14 visits, and drug treatment from 4 to an average of 3 psychotropic drugs.

Conclusion: In addition to an improvement in clinical symptoms, the VNS method might enable an amortisation of costs.

References

• 1 Alonso J, Angermeyer MC, Bernert S. et al . Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project.  Acta Psychiatr Scand Suppl. 2004;  ▪ 47-54
  PubMedGoogle Scholar
• 2 Bijl RV, Graaf R de, Hiripi E. et al . The prevalence of treated and untreated mental disorders in five countries.  Health Aff (Millwood). 2003;  22 122-133
  CrossrefPubMedGoogle Scholar
• 3 Daban C, Martinez-Aran A, Cruz N. et al . Safety and efficacy of vagus nerve stimulation in treatment-resistant depression. A systematic review.  J Affect Disord. 2008;  110 1-15 , Epub 2008 Mar 28
  CrossrefPubMedGoogle Scholar
• 4 Sperling W, Kornhuber J, Wiltfang J. et al . Combined VNS-rTMS treatment in a patient with therapy resistant depression.  Pharmacopsychiatry. 2007;  40 39-40
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society.  Br J Psychiatry. 2002;  180 227-233
  CrossrefPubMedGoogle Scholar
• 6 George MS, Rush AJ, Marangell LB. et al . A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression.  Biol Psychiatry. 2005;  58 364-373
  CrossrefPubMedGoogle Scholar
• 7 Greenberg PE, Kessler RC, Birnbaum HG. et al . The economic burden of depression in the United States: how did it change between 1990 and 2000?.  J Clin Psychiatry. 2003;  64 1465-1475
  CrossrefPubMedGoogle Scholar
• 8 Groves DA, Brown VJ. Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects.  Neurosci Biobehav Rev. 2005;  29 493-500
  CrossrefPubMedGoogle Scholar
• 9 Hakkaart-van Roijen L, Hoeijenbos MB, Regeer EJ. et al . The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands.  Acta Psychiatr Scand. 2004;  110 383-392
  CrossrefPubMedGoogle Scholar
• 10 Kennedy SH, Giacobbe P. Treatment resistant depression – advances in somatic therapies.  Ann Clin Psychiatry. 2007;  19 279-287
  CrossrefPubMedGoogle Scholar
• 11 Kessler RC, Berglund P, Demler O. et al . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).  JAMA. 2003;  289 3095-3105
  CrossrefPubMedGoogle Scholar
• 12 Nemeroff CB, Mayberg HS, Krahl SE. et al . VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms.  Neuropsychopharmacology. 2006;  31 1345-1355
  CrossrefPubMedGoogle Scholar
• 13 Sackeim HA, Rush AJ, George MS. et al . Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome.  Neuropsychopharmacology. 2001;  25 713-728
  CrossrefPubMedGoogle Scholar
• 14 Salize HJ, Stamm K, Schubert M. et al . Cost of care for depressive disorders in primary and specialized care in Germany.  Psychiatr Prax. 2004;  31 147-156
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Sperling W, Reulbach U, Maihofner C. et al . Vagus nerve stimulation in a patient with gilles de la tourette syndrome and major depression.  Pharmacopsychiatry. 2008;  41 117-118
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Wittchen HU, Holsboer F, Jacobi F. Met and unmet needs in the management of depressive disorder in the community and primary care: the size and breadth of the problem.  J Clin Psychiatry. 2001;  62 ((Suppl. 26)) 23-28
  PubMedGoogle Scholar
• 17 Wittchen HU, Knauper B, Kessler RC. Lifetime risk of depression.  Br J Psychiatry Suppl. 1994;  ▪ 16-22
  PubMedGoogle Scholar

1 Each author contributed equally to this work.

Correspondence

W. SperlingMD 

Department of Psychiatry and Psychotherapy

University Hospital of Erlangen

Schwabachanlage 6

91054 Erlangen

Germany

Phone: +49/9131/853 61 94

Fax: +49/9131/853 60 02

Email: Wolfgang.Sperling@uk-erlangen.de